Company news
InflaRx N.V. news in 2022
InflaRx N.V.'s news releases, calls and decks from 2022, newest first.
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
December 20, 2022
InflaRx Reports Third Quarter 2022 Financial & Operating Results
November 8, 2022
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
November 8, 2022
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
September 28, 2022
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
September 7, 2022
InflaRx Reports Second Quarter 2022 Financial & Operating Results
August 4, 2022
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
July 25, 2022
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
July 5, 2022
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
June 28, 2022
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
May 11, 2022
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
March 30, 2022
InflaRx Reports Full Year 2021 Financial and Operating Results
March 23, 2022
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
March 16, 2022
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 7, 2022
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
February 27, 2022
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
February 15, 2022
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 9, 2022
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
January 4, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 33 slides · September 2022
- Investor Presentation (January 2022)
Investor deck · 31 slides · Jan 10, 2022